Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-10-29
2003-05-13
Fredman, Jeffrey (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023100, C536S023500, C536S023400
Reexamination Certificate
active
06562800
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a composition and method for inducing an immune response. In particular, the invention relates to nucleic acid expression vectors encoding immunopotentiating chemokines as well as immunogenic polypeptides. The invention also relates to methods of manufacturing various immunogenic compositions, and methods of using such compositions to treat cancer and infectious disease.
BACKGROUND OF THE INVENTION
The immune system protects individuals against disease and infection by viruses, bacteria or other infectious agents. The immune system is able to recognize cells of different individuals, including different allogeneic hosts. Ideally, the immune system functions to eliminate an infectious agent from a mammalian host. Specific immune mechanisms are involved in presenting infection with foreign agents, in resolution of such infections, and in control of cancer cells. Resolution of most virus infections (as well as infection with many other intracellular agents) and elimination of cancer cells is the result of a successful cellular (e.g., T
h
1 helper T cell and cytotoxic T cell) immune response. The cellular immune response results from activation of certain lymphocytes known as T cells.
Many traditional vaccines expose the immune system to a foreign antigen such as an antigen of an infectious agent to elicit an antigen-specific immune response. The immune response is often predominantly humoral, in which the presence of a foreign antigen elicits the production of antibodies specific for the antigen. For example, an infectious agent antigen may elicit the production of antibodies which neutralize the infectivity of the infectious agent or toxin produced by the agent. Examples include polio and hepatitis A and B, measles, Varicella-zoster, parvovirus and rabies virus antigens. Toxic antigens produced by infectious agents include tetanus toxin, botulinum toxin, diphtheria toxin and pertussis toxin. (See Fundamental Virology, Fields et al. eds., 3rd ed., Lippincott-Raven, New York 1996; and Microbiology, Davis et al. eds., 4th ed., Lippincott, New York, 1990). This is in contrast to a cellular response, e.g. by activated T cells.
Recently, vaccination using DNA fragments has emerged as a viable method for inducing an immune response in animal hosts. DNA vaccination has enormous potential to revolutionize human health by obliterating many infectious diseases, not only in the industrialized nations but also in the Third World. There have been intense efforts to develop vaccines that induce a protective response based on induction of antibodies or cellular responses. Recent studies have shown that DNA vaccination involving the direct injection into animals of genes encoding viral proteins (subunit vaccines), rather than attenuated or killed viruses, can evoke a protective effect against challenge with whole virus from which the gene was derived [Donnelly, J. J. et al.;
Annu. Rev. Immunol
. 15:617-648 (1997)].
Thus, direct injection into animals of a DNA expression vector, encoding a potentially pathogenic protein, has demonstrated that a protective specific immune response, both humoral and cellular, can be elicited to that protein product. It is thought that bone-marrow-derived, antigen-presenting cells (APCs) take up the DNA plasmid and express the encoded gene product in the lymph nodes—the tissue in which an immune response is orchestrated. This ultimately results in the generation of specific antibodies and cytotoxic T lymphocytes.
The use of subunit vaccines suffers from at least two limitations, namely, (i) the presence of certain viral proteins, e.g., HIV gp160, can themselves have deleterious effects even in the absence of infectious virus (Mellado, M., et al.;
Vaccine
15:1111-1115 (1998)) and (ii) expression vectors can only be constructed to contain a limited number of genes (10-15 kb). Thus, a DNA vaccine which presents several viral proteins for recognition by the immune response must comprise a mixture of plasmids each containing 1-3 genes, which limits the amount of each vector species that can be administered.
As a consequence, there is a need to minimize the size of sequences necessary to elicit a protective immune response. The minimization of sequence size will allow the use of small vectors, which enter cells more efficiently than larger vectors, and obviate the potentially harmful effects associated with expression of whole viral proteins.
SUMMARY OF THE INVENTION
The present invention features a novel DNA expression vector for inducing an immune response in a mammalian host that includes at least one sequence encoding an immunogenic polypeptide and at least one sequence encoding an immunopotentiating chemokine capable of boosting the host's immune response to the immunogenic polypeptide. The chemokines of the invention are preferably selected according to the animal to be treated, e.g., murine chemokines if the animal is a mouse or human chemokines for human beings.
In another aspect of the invention, the DNA expression vector is combined with a suitable carrier to yield a pharmaceutical composition that would be effective in inducing an immune response in the host.
The invention also relates to a method of inducing an immune response in a mammalian host by administering an effective amount of the pharmaceutical composition. The immune response may be in the form of a protective challenge or a therapeutic effect.
Additionally, the invention features a method for manufacturing pharmaceutical compositions comprising the step of combining the DNA expression vector of the invention with an acceptable carrier.
REFERENCES:
patent: 5846546 (1998-12-01), Hurwitz et al.
patent: 5935568 (1999-08-01), Dow et al.
patent: WO 97/15594 (1996-10-01), None
patent: 99-29728 (1997-12-01), None
Shiver et al., Humoral and Cellular Immunities Elicited by HIV-1 DNA Vaccination, Journal of Pharmaceuitical Science, Dec. 1996, vol. 85, No. 12, pp. 1317-1324.*
Kim et al., Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens, 1998, Eur. J. Immunol., vol. 28, p. 1089-1103.*
Wu et al., Engineering and intreacellular pathway for major histocompatibiliy complex class II presentation of antigens, Dec. 1995, Proc. Natl. Acad. Sci., p. 11671-11675.*
Lee et al., Major histocompatibility complex class I presentation of exogeneous soluble turmor antigen fused to the B-fragment of Shiga toxin, 1998, Eur. J. Immunol., vol. 28, pp. 27226-2737.*
Denis et al., Vaccinatin with Plasmid DNA Encoding Mycobacterial Antigen 85a Stimulates a CD4+ . . . , Apr. 1998, Infection and Immunity, vol. 66, No. 4, pp. 1527-1533.*
An et al., A Multuvalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and Th Epitopes . . . , Mar. 1997, Journal of Virology, vol. 71, No. 3, pp. 2292-2302.*
Nathason et al., Biological Consideration in the Development of a Human Immunodeficiency Virus Vaccine, pp. 579-589.*
Aderson et al., Human gene therapy, Apr. 30, 1988, vol. 392, Nature, pp. 25-30.*
McClusklie et al., Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primate Molecular Medicine, 1999, vol. 5, pp. 287-300.*
Bonecchi, R. et al., “Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1T Helper Cells (TH1s) and Th2s,” J. Exp. Med., The Rockfeller University Press, vol. 187, No. 1, Jan. 5, 1998, pp. 129-134.
Siveke, J. et al., “Cutting Edge: T Helper 1 and T Helper 2 Cells Respond Differentially to Chemokines,” The American Association of Immunologists, 1998, pp. 550-554.
Zingoni, A. et al., “Cutting Edge: The Chemokine Receptor CCR8 is Preferentially Expressed in Th2 But Not Th1 Cells1,2,” The American Association of Immunologists, 1998, pp. 547-551.
Mellado, M. et al., “HIV-1 Envelope Protein GP120 Triggers a Th2 Response in Mice that Shifts to Th1 in the Presence of Human Growth Hormone,” Eisevier Science Ltd., vol. 15, No. 11, 1998, pp. 1111-1115.
Baggiolini, M., “Chemokines and
Angell Jon E
Bingham & McCutchen LLP
Fredman Jeffrey
University of Southern California
LandOfFree
Use of immunopotentiating sequences for inducing immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of immunopotentiating sequences for inducing immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of immunopotentiating sequences for inducing immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3029588